Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

NC-1800 now in phase II development

Sep. 15, 1997

PharmaPrint begins phase II trial of herbal treatment for BPH

Sep. 11, 1997

Pharmacia & Upjohn's urinary incontinence treatment approved in Sweden

Sep. 9, 1997

Agents useful for BPH from Pfizer

Sep. 9, 1997

Attenuation of cyclophosphamide-induced bladder damage in animals by GR-203040

Sep. 9, 1997

Uroselective alpha1-adrenoceptor antagonists for BPH

Sep. 8, 1997

Antioxidant from Otsuka effective in animal model of nephritis

Sep. 5, 1997

New aldosterone antagonists from Yamanouchi

Aug. 26, 1997

ETA/ETB antagonist protects against renal insufficiency in canine model

Aug. 19, 1997

Clinical trial results announced for novel incontinence therapeutic

Aug. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.